Palvella Therapeutics, Inc. has announced the commencement of dosing in its Phase 3 SELVA trial, aimed at evaluating QTORIN™ ...

“The simple answer is that we don’t know yet,” says Leslie Kenny, a longevity expert. What we know so far is that “rapamycin ...

Cancer remains one of the leading global causes of mortality, with an estimated increase in cases due to lifestyle, environmental, and genetic ...

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third ...

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...